Issues
-
Cover Image
Cover Image
Breast cancer is the second most common cause of cancer-related death in American women. A variety of treatment options are available for ER-positive breast cancer; however, these agents are not effective against ER-negative breast cancer, an aggressive disease which is typically treated with conventional chemotherapy and carries poor prognoses. Mammalian target of rapamycin (mTOR) is a crucial mediator of tumor progression and may be a promising target for ER-negative and triple-negative breast cancer. In the study starting on page 791, Mazumdar and colleagues demonstrate that the mTOR inhibitor everolimus delays (and, in some cases, completely prevents) tumor development in multiple models of ER-negative breast cancer by controlling the proliferation of mammary glands and tumors. Their results suggest that long-term treatment with everolimus is a safe option for the prevention of ER-negative and triple-negative breast cancer. The cover image depicts that everolimus treatment significantly reduces mammary gland proliferation measured by Ki67-positivity in genetically engineered mouse models. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Highlights from the Literature
Spotlight
Research Articles
Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer
Our results show that everolimus delays mammary tumor formation in multiple mouse models, suggesting that mTOR inhibitors will be useful for the prevention of ER-negative and triple-negative breast cancer in humans.
Microbes Contribute to Chemopreventive Efficacy, Intestinal Tumorigenesis, and the Metabolome
This study demonstrates novel mechanisms by which chemopreventive agents exert their effects and gut microbiota impact intestinal tumor development. These findings have the potential to lead to improved cancer prevention strategies by modulating microbes and their metabolites.
Differences in Prostate Cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different?
Older age at diagnosis is consistently associated with worse clinical outcomes in prostate cancer. This study with independent discovery and validation sets and long-term follow-up suggests that prevention of lethal prostate cancer should focus on implementing appropriate screening, staging, and treatment among older men without expecting fundamentally different tumor biology.
Blood Lipids and the Risk of Colorectal Cancer: Mendelian Randomization Analyses in the Japanese Consortium of Genetic Epidemiology Studies
In this large MR analysis of a Japanese population, a positive association was found between genetically predicted high total cholesterol (TC) levels and an increased risk of colorectal cancer. Therefore, lowering TC levels by lifestyle modifications or medications may be justified for the purpose of preventing colorectal cancer.
Aspirin-Mediated Prevention of Colorectal Adenomas Recurrence is Affected by Blood Biochemistry and Nutritional Intake
Aspirin has been shown to prevent the onset of colorectal adenoma and cancer, and its effect modifications have been analyzed. Lipid metabolism and liver function were correlated with the suppressive effect of aspirin on the recurrence of colorectal adenoma.
Endoscopic Screening and Risk of Colorectal Cancer according to Type 2 Diabetes Status
The endoscopic screening-associated ARRs for colorectal cancer incidence and mortality were higher for individuals with T2D than those without T2D. Endoscopic screening confers a greater benefit for colorectal cancer prevention among T2D individuals, who may also benefit from an earlier screening than the current recommendation.
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.